OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Company registration number 07272699 (England and Wal￿> Charlty wlstratlon numb•r 1137689 (England and Walèsl Charlty reglstrntlon number SC049777 Iscotlandl PANCREATIC CANCER ACTION ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

PANCREATIC CANCER ACTION LEGAL AND ADMINISTRATIVE INFORMATION Trustees N Menezes R Legg C Carter E Cowan N Longworth G Codacci Pisanelli D Slater G Lesro T Matthews Secretary T Matthews Chorlty numbgr IEngland ond Wal•81 1137689 Ch•rlty number IS¢otlondl SC049777 Company numb•r 07272699 PrlncSpal addr•s• Suite 3.10 Covauft Fullarton Road Cambu51ang Glasgow G32 8YL R•gl8t¢r•d offl¢• 3 London Square Cross Lanes Guil(Iford GU1 1UJ Audltor liotts LLP 3 London Square Cross Lanes Guildford GU1 1UJ Correspondence address Suile 3.10 Covault Fullarton Road Cambu51ang Glasgow G32 8YL

PANCREATIC CANCER ACTION CONTENTS Page Chief Executive's foreword Trustees, report 2-10 Statement ol Trustees, responsibilflies Independent auditorfs report 12- 15 Slalemenl ol financial 8ctiviti'e8 18 8alan¢e shegl 17 Statement of cash flows 18 Notes to the financial s(a(ements 19-32

PANCREATIC CANCER ACTION CHIEF EXECUTIVE'S FOREWORD FOR THE YEAR ENDED 31 DECEAIBER 2025 Chl•f Ex•cutlv•'s Fof•word Although l joined Pancreatic Cancer Aclion after the period covered by this report, l am delighted to have the opportunity to reflect on the charity's work and achievements over the past year. These achievements are testament to the dedication of our staff. trustees and volunleers. and to the generosty and commitment of our supporters. fundraisers and partners across the UK. Pancreatic cancer remains one of the toughest cancers, wilh survival rates improving far too slowly. Too many people are still diagnosed at a late stage, when treatment options are limrted. This makes our mission more important and urgent than ever. Earty diagnosis can give people more Irealment opts"ons, more time wth those they love and the best possible chance ol survival. Throughout the year, PanC￿atIC Cancer Aclion continued to raise public awareness of the signs and symptoms. provide trusted information and support to people affected by the disease. antj work wrth hearthcare professionals and researchers to irnprove eaty diagnosis. None of this work would be possible without the people who share their experiences, raise vital funds. Campaign alongside us and help us reach communrties across the country. Since joining as Chief Executsve. I have been 5tru¢k by the passion. expertise and detemiination that exist throughout our Community. I have also seen Ihtr s¢ale of Ihe thallen9e ahead. Meaningfvl progress will require us lo remain focustrd, use tsur r¥$ources ¢arefulty and work collaboratively with people affected by pancr&ali¢ cgncer, healthcare professionals, researchers, polscymakers and other organIsa￿onS that share our ambitions. As we look to the future, we will build on Ihe strong loundations created by those who have supported and shaped the charity. We will continue to put eaty diagnosis al the heart of everything we do and focus our efforts where we believe Pancreatic CancerAction can make the greatest difference. Thank you to everyone who has contributed to our work during the year. Your support, commitrnent and belief in our mission make our work possible. I look forward to working alongside you as we tske ihe chanty into rts next chapter. P.J. H_f..J Paula Hanford Chlel Executlve Offlc•r 18 Sep 2026 Dale.,

PANCREATIC CANCER ACTION TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) FOR THE YEAR ENDED 31 DECEAIBER 2025 The Trustees present their annual report and financial ststements for the year ended 31 December 2025. The finanaal statements have been prepared in accordance with the accounbng poliaes set out in note 1 to the financial statements and compty with Ihe charity's Articles of Associabon. the Cornpanie5 Act 2006. the Charities and Trustee Inve5trnent Iswtlandl Aot 2005. the Chaiities Accoun15 Iscouandl Regulation5 2006 las arnendedl and 'Accounting and Reporting by Charitses. Staternent of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Repo￿"n9 Standaid applicable in the UK and Republic of Ireland IFRS 1021 leffective l January 20191". Oblectlves and actlvltles Our purpose Pancreatic Cancer Action works to save lives through promoting eaty diagnosis of pancreatic cancer. We do this through promoting g￿ater awafeness of the symptoms ol the disease. the funding and development of medical educational programmes. SUPPOrting patients through improved information about pancreat￿ cancer either on our website or in print and by funding research. Our vlslon Our vislon 1$ that ev¢ryon$ survNo$ pan¢reati¢ Can￿r. Our ml881on Our mission is to improve survival rates of pancrealic cancer by ensuring more people a￿ diagnosed earfy and that everyone has access to effeC￿ve treatments. supporf. information and care. Obl¢¢tlv•s The charty's oblectlves arè.. Awarenes8 - increase public awareness and knovAedge of pancreatic ncer and its 5ymptom5 to achieve earty diagnosis Campalgn and lobby the 9ovemment and key stakeholders for chon98 lo advance the standard of heatt￿￿ for individuals affected by panC￿atIC cancer Traln and proviilè pIon￿ring odu¢alional resour¢¢$ for our m8ai¢al and healthcare communities Innovatlve research we lund il. we support it - lo improve earfy diagnosis and develop effective treatments lo improve pancreatic ¢an¢trr outcomes Offer Ihe proviS￿Tr ol praclical and enKJtM)nal support and inlormation to all affected by pancreatic cancer Now - we are the action chanty and action Is needed mre than ever before1 The Trustees have paid due regard to guidan￿ issued by the Charity Commission in deriding what activities the charity should undertake. Tho Trusttès. aetiviti6s The Trustees meet regularly to develop and support strategies to meet the chantable objectives. The Trustees currenty have a range ol skills and experience Ihat range from medicavsaenlffjc. legal, corporate govemance, finan￿ and PR, direct and indirec¢ lived experience ol pan￿atIC cancer. Role of volunteers I PCA Action Ambassadof3 The Charity receive5 the very welcome as51Stance of volunteers. who help support a range of projects tts raisè awareness of pancreats"c canor, provide support, miew literature and lundraise in their communrt*s. The charity seeks volunteer assistance via the website, social media and by word of mouth. Publi¢ benefit statement The Trustees Gonfirm that Ihey have complied wilh the duty in Sedion 4 of the Charrbes Act 2011 to have due regard to the Charity Commission's general guidance on public beneffi.

PANCREATIC CANCER ACTION TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Aehl•v8ments and p8rformaneè Below are the highlights of our activty and work in 2025 in pursuit of our ongoing mission to improve survival rates of pancreatic cancer by ensuring more people are diagnosed eaty and have access to effective treatments, support, inforrnation and rare. q. Awareness - increase public aknvrenvJs ond knoledge of ￿ncreatI¢ ¢¥ncer and Its •ymptoms to achlèv• •a￿Y dlagnosls Pancreatic Cancer Action provides individuals. communrties and organisalions with resources to help raise and improve syrnplom awareness of pancreatic cancer. Through posters. leaflets, booklets, online resources, and community-based activities, we aim to equip people with Ihe kno¥￿edge they need to recognise potential syrnptoms and seek medic81 advice prompty. Raising symptom awarène$$ is ¢entral to our mission lo improv& earty diagnosis and save livtrs. By helping people recognise thè signs and symplom$ of pancreats¢ ¢anc•r, we encourage anyonè wth concèrns to conla¢t thèir GP as as possible. Our accredited health infomialion resources are available in both digrtal and printed fomats. In our commitment to making high-quality heatth infornialion accessible lo a wide range of communities our key pancreatic cancer awareness materials are available in larger print. braille and have also been Iranslated lor the six languages of Polish. Urdu, Punjabi. Bengali. Arabic and Guiarab. io assisl people who do not have English as their first language. Throughout 2025, we continued to raise awareness of Ihe signs and symptoms of p8n¢reali¢ cancer in a variety of ways. Our dedicated staff and volunteers played an important role In engaging directly with communities, inltialing conversations about symptom awareness and reinforong the importance of earfy diagnosis. Our distinctive purple-branded Pancanvan. displaying key symptom infomiat)n, also helped us reach the public by being positioned in prominent. high-footfall and high-traffic locations. The striking mural of The Smrths bassist Andy Rourke. located on Ihe side of The Wheatsheaf Pub in Manchester's Northern Quarter. continued to raise both awareness 8nd lunds for pancreatic cancer. Originally unveiled on Worfd Pancreatic Cancer Day in 2024 as a tribute lo Andy's lile and legacy. the mur81 has since beeome part of a popular tourist mural trail and a poignant dèstination lor fans visrtin9 from around the worfd. We are grateful to the team at The Wheatsheaf Pub for their contsnued support of our awareness Inrtiatsves, including the use of Pancreatic CancerAclion beer mats displaying inforniation about the syrnptoms ol pancreatic cancer. For Pancreatic Cancer Awareness Monlh IPCAMI in November. we launched our new %DeadlyKillerf carnpaign, which showcased thal pancreatic cancer is the deadliesl cornmon cancer and that spotting the signs early could save live5. We highlighted th81 it strikes fasl. hi(Jes behind ordinary symptoms. an(J too often goes unnoticed until il's loo late. The Gampaign was hard-hrtting. highty visual and aiffled lo expose the truth. pancre8tic can￿r is 8 silent killèr that doesn't wait or discriminate. Recoynising thè symptoms tayty and acting fast ¢ould vdv¢ 3 Irf&. When you know the signs, you have a chance to fight back against this deadly killer. The C￿allon of our '#Dead￿Killerf campaign was made possible once again by the support we received from FREE Partners. who gifted their time and experts.se to create the campaign as part of their Free Love Initiative. We are incredibty grateful lo work wrth this award-winning creative agency to develop impathl eye-catching campaigns that provoke a slrong emolional response. To extend the campaign's ￿a¢h. we invesled in digital and Oul-of-Home IOOHI advertising, complemented by 0rg8nic media wverage across traditional and digital channels. This inrjuded news wverage and interview5 on local radio and television. helping us take our symptom-awareness message to wider audiences 8ClOSS the UK. Our speci81 thanks go to the survivor5 8nd bereaved famity wnembers who sh8fed theif experiences 85 part of the campaign and support media engagement all year-round, helping spouight real families affected by pancreatic cancer through the power of case studies in print an¢J online. Wilh an urgent need to improve public awa￿ness, education and understanding of pancreatic cancer. together. we can encourage more people to recognise potential syrnptoms and seek medical advi￿ prompty.

PANCREATIC CANCER ACTION TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 In addth.on to our #Dead￿Killerf campaign some in¢￿dible activrties and events happened throughout November that raised awareness and generalerj income. We continued lo support collaborative awareness campaigns wlh Lights UK and the World Pancreatic Cancer Coalition, joining a global community united in raising awareness ol pancreatic cancer. Throughout November 2025, and particularty on World Pancreaty'c Cancer Day. supporters helped to illuminate buildings and 18ndtnarks in purple, shining a light on the disease and cxe8tsng Opportunities to share vit81 syrnptOTn information. These initiatives bring communities together and demonstrale the collectNe detemination to Improve outctsrnes and survival for people affected by pancfeatic cancer. We also invested In new resources to strengthen our communty awareness activities, including new pop-up banners, branded table covers. faster card donation laalrties and pancreas4haped display boards. Together with the limited-edition purple Tunnock's Teacakes generousty provided lo the charity. these resources helped attract attention and provided valuable opportunrties to start conversations Jbout pancreatic cancer during Pancreatic CancerAwarenes5 Month. With the continued support of Neh¥ork Rail. Pancreatic Cancer Action mainlained a presence 81 major railway st8tions across the UK, including Leeds. London Wdterloo, Edinburgh Wdverfey and Glasgow Central. These busy locatsons with high foomalls, ènablè our staff and volunteèrs to èngage with thousands of pèoplè, shar¥ Inlormatlon about the signs and symptoms of pancreatic cancer and raise vrtal funds. Our annual 'Purple Takeover, of Glasgow Central Slalion was once again a highlight of Pancreatic Cancer AWa￿nesS Month. Organised by one ol our dedicated supporters. the event brought together volunteers, supporters and performers for a memorable day of awareness and lundraising. Entertainment included the Glasgow Rock Choir and The KC Communty Choir. vtho generousty returned to support the event. wilh some new additions in 2025. induding The Kirkinlilloch Pipe Band. The performances drew the attention of comrnuters and visitors. ￿aling valuable opportunitie5 for our volunteers and team members 10 engage vthh Ihe public. r8i$e awareness of the signs and symptoms of pan¢re8li¢ ¢an¢er 8nd ¢oll¢¢t vital fund$ lo support our work. Many people also ¢ho$& to 1&8v& 8 purple heart in memory or recognition of a loved one affected by pan￿at1¢ cancer.. a moving tradits'on that has become a meaningful part ol the event over the years. We are incredibly grateful to our dedicated staff, volunteers and supporters who give their time. energy and enthusiasm throughout the year lo raise awareness and fvnds in communities across the UK. from busy shopping cenlres and raihyay slalions to local rvgby dubs and community events. Our thanks go to every mernber ol the public who stops to talk. leam more aboul pancrealic cancer or support our work. Every ¢onver8atlon 18 an opportunlty to In¢re¥￿ ¥ymptom owor¢nM$, •n¢ouro9• ￿rI1•r dlogno818 and, uliim4iely, h•lp 1ov* liv¥¥. 2. Campaign and lobby government and key ¥takeholdern for ¢h#ny io odv•n¢¢ th# $tsndord of heolth¢are for people affected by pancreati¢ ¢an¢pr With pancreatic cancer Incidence increasing. urgènt action is n8eded to improvè awarèness, earfy diagnosis, treatment, patient experience and survival. Pancreatsc Cancer Action continues to advocate on behaw of patients and families, engaging with govemments, MSPS, MPS. councillors and other key stakeholders to ensu pancreatic cancer remains firnity on the political and heamhcare agenda. Throughout 2025, we continued (o work in partnership with Cancer52, One Cancer Volce, the Less Survlvable Cancers Taskforce, the Scottlsh Cancer Coalltlon, the North Cancer Alllance Iscotlandl, Wales Cancer Alliance and other organisations and coalitions working to improve cancer outcomes. By working collaborativety. we strengthen our wlledive voice and help ensure that the experiences and needs of patients 8nd c8rers remain at the heart of policy development and govemment deas10￿Making. The first Less Survivable Cancers Awareness Week took place 13￿19th January 2025, building on previous success of Less Survivable Cancer Awareness Day. Organised by The Less Survivable Cancer TaSkfQr￿ of which we are a supports'ng member, the aim is lo raise awareness ol the need to improve outcomes of brain, lung, pancreatic, liver. oesophageal and slomach cancers. These six Can￿rS are responsible for hall of all common cancer deaths and up to a quarter of all rancer cases. Together. wth other ¢haritie5 in the taskforce. we carnpaign for improvernents in awareness. diagnosis and research. to d05e the deadty cancel gap and save lives. Events took place acro55 all 4 nats'ons of the UK and we were pioud to attend a ieception at Scottish Parfiament.

PANCREATIC CANCER ACTION TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Vve have engaged individually and Collective￿ wrth govemments and polwmakers throughout the year, providing evidence, insight and the perspectives of people affecled by pancreats'c Can￿r. During 2025. Pancreatic Cancer Aclion provided input to Ihe development of Ihe UK Govemment's National CanTrr Plan. helping to ensure that the experiences and needs of people affected by pancreatic cancer were represented. We continued to be an active partner in campaigning for ¥nprovements in pancreatic cancer diagn051S. treatment and care acros$ England and Wdles. This included our ongoing involvement with the National Pancreatic Can¢erAvdft. Pancreatic Cancer Action had advocated for an audrt ol pancreatsc cancef dia9nosis and treatment for many years, eontributing to 8 feasibility study in 2022 an¢J the development of a scoping document in 2023 to help identify priorities for pancreatic cancer care. Following publication by the National Cancer Audrt Collaborating cent￿ INATCANI of its State of the Nation Report in September 2024, covering care received by people diagnosed with pancreatic cancer in England and Wales, we continued during 2025 to advocate for the audrt's findings and recommendations to translate into meaningful improvements in practi￿. We believe the evidence generated through Ihe audrt provides an important opportunity to drive p05rtive change, inform the development ol guidelines, improve early dete¢iion and diagnosis, addre5$ v8ri81ions in care and Ultimate￿ improve the experiences and outome$ ol people affe¢t&d by pan¢reab"¢ ¢anc¥r. In November, represen¢8lives from Panc￿811¢ Cancer Action and Pan¢reali¢ C8ncer UK joined Members of the Scottish Padiament for a cross-paty photocall, demonstrating united support for people affected by pancreatic cancer and their families. We provided MSPS with briefings ahead of the annual Scottish Parfiament debate marking Pancreatic Cancer Awareness Month. which took place on Worfd Pancreatic Cancer Day. 20 November 2025. During the debate, MSPS rellected on the impacl of pancrealic cancer wthin Iheir communities. ￿Cognised the contribution of patients. families, volunteers. lundraisers and charities. induding Pancreatic Cancer Action, and called on the S¢ollish Government to accelerate adion and ￿mmitmentS io improvtr pan¢reab¢ ¢8n¢er out¢ome$. We continued lo carnpaign for the leaming and improvements achieved through the SHPBN Pathway Improvèmènt Projèct for pancrèatic and hèpatocellular cancer ISCOT-HPBI to ￿ embedded into fijture practic&, lundlng and service development. As a key chanty partner in the SCOT-HPB project, Pancreatic Cancer Action was proud to conlnbule to work that demonstrated improvements in the pathway from suspicion of cancer through to diagnosis and treatment. The project also achieved positive advances in bmety and coordinated communication. benefiting palienls, Ca￿r$ and healthcare prolessionals. In Novernber 2025, Ihe results of the pathway improvement project We￿ published in The European Joumal of Surgical Oncology IEJSOI. enabling the leaming and achievemenls of Ihe project to be shared beyond Scotland. Peer reviewed by experts. the publication in the highty repulable medic81 joum81 was a 5ignific8nl athievemenl lor all that were involved in the pioneerin9 Pathway ImpTovement project. This was also ￿ferenCed by MSPS during the annual Scottish Parliamenl debate, helping to shine a spouight on Ihe progress achieved and the need lor further action. The annual Scottish Cancer Conference which took place in November 2025 at the University of Strathctyde's Technology and Innovats'on Centre included discussions on the updated Scottish Cancer Referral Guidelines, published in 2025, which incorporaled ￿commendatIOnS from Pancreatic Cancer Action. While progress is being rnade. the pace of improvement musl accelerate. Pancreatic Cancer Action will continue to pre53 for change and represent the voices and experiences of patients and carers, building on many years of C8rnpaigning and collectNe 8Ction by our ci)fflmunrty- We will continue to work a10￿gS1de patients. families, heaNh¢8re profr$sional$, poliwnakers and p8rtner organisations tts inlluence meaningtul and lasting change. Our focus remain5 dear". earty diagnos15. better patient experiences. improved acee#s to timely and èffectlv• caro, and ultlmat•ly, morè Il¥t$ sav•d Irom pancrnatlc cancer.

PANCREATIC CANCER ACTION TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 3. Traln and provldè plon••rlng •dueatSonal r•soure•s lor our m8dleal and healtheam communltl•s. Pancreatic Cancer Action provides PKJneering accredrted e4eaming for healthcare professionals which contribute3 to their Continuous Professional Developmenl ICPD} requirements. Our GP e-18arning module is hosted by The Royal College of General Piactitsoneis IRCGPI. Our Phamacy Team e4eaming module is hosted by The Royal Phamaceutical Society IRPSI, British Oncological Phamiaceutical Assoaation IBOPAI, The NHS Leaming Hub and ELE Leam. Throughout 2025, we continue¢J to Pfovide GP and phamiacy infomation packs across the UK. We are grateful to our dedicated community of volunteers. who play an important role in distributing these resources and raising awarenes5 Wlthin their local comrnunities. In November 2025 we attended a GP Awareness Event in Dunstable. which provided a unique opportunity to engage with GPS and local patients. Wh a presentation on raising awarene55 of pancreatic cancer. pancre8tic health and diabetes management we were able to shine a li9hl on Ihe importsnce of awareness and education and provide resources lo share wrth wider public and heamhcare professional netwoths. We look lo￿ard to ¢ontinuing our woth wrth m&di¢al and hèalth¢arè prof&s$ional$ to improvo awar¥n¢$s and &du¢ation. and ultimatety support the eadier tlw9no$6s of panue* ¢an¢er. 4. Innovatlv• r•8•areh w• fund It, w• •upport It to Improv• èarty dlagnosls and d•v•lop •ff8etlv• tr•atm•nts to Improv• pancr•atle eanc•r outcom•8. Pancreatic Cancer Action has a strong track fecord ol providing pump-priming seed funding lo kick-start innovative research projects. helping promising ideas generate the evidence needed to attract larger-scale investrnent frorn other funders. A5 a small charity. we are not in a position to invest millions of pounds in research on ttte same scale as larger organisations. Instead. we focus our resources where we believe Ihey can act as a catalyst for innovation and further investment. We a￿ proud lo support tsrgeted ￿SearCh projects thal use dala and Science lo improve our undsrstanding ol pancreat￿ cancel and explorè new opportunrtiès lor èarfier diagnosis and morè èffèctiv¥ treatment. A powerful èxamplè of this approad) is our ongoing partnèrship wrth Dr Agnieszka Lemanska and the research team at the Universrty of Surrey. Pancreabc Cancer Action provided initial funding lor research examining the relationship tse￿een diabetes and pancreatic Can￿1. The retrospective case-control study analysed a large sample of GP records from people with diabeles. comparing those who subsequentty developed pancreatic cancer wth those who did not. The findings helped build the evidence for a proactive case-finding approach focused on people with new-onsel diabetes and unexplained weight loss. PanrJeatic Cancer Action cOn￿'nued to work wilh the Universty of Surrey 8nd NHS England as thè work developèd. In 2025, NHS Enyland launchèd a Ihrèe-year pilot, backed by almost £2 million of targeted funding, through which more Ihan 300 GP practices In England would search patient records to identify people aged over 60 wth new-onset diabetes and unexpected weight loss and refer those considered al risk lor further investigation. This represents an important step towards translaling research into dinical practice. The pilot seeks to proactively identify people who may be at increased risk of pancreatic cancer and offer further investigation (o confimi or rule out the disease. with Ihe potential lo support earty diagnosi5. For Pancreatic Cancer Action, this demonstrates the significant impact that carefulty t8rgeteil seed lunding ran have. Our initial investment helped innovats.ve ieseaich piogress to a much laiger4CAle progiammè, attracting substsnb.al addrtional funding and ¢￿atIng the potential to benefft many more pth"ents. We are committed to supptsrting further innovath.ve research the potents.al to advance earty diagnosis and improve outcomes for people affected by pan￿at1¢ cancer. We continue to be proud members of The Assouation of Medical Research Chariiies IAMRCI and follow their best practi￿ research gU￿elIneS. Our contribution to research extends beyond providing funding. Pancrealic CancerAction also plays an important role in supporting the wder ￿searCh communty by ensuring that the voices and lived experiences of patients and carer5 are represented.

PANCREATIC CANCER ACTION TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Through Patient and Public Involvement IPPl}, we support researchers and research projects to incorporate the perspectives of people affected by pancrealic cancer throughout Ihe research process. Meaningful involvement ol patients and carers helps ensure that research questions. prionties and approaches reflect what matters to those with lived experience of the disease. In May 2025 we provided support and attended The London P8ncre8s Workshop - a forum for state of the art clinio81 8nd basic research in pancre81ic Con￿[. Organised by members of The Queen Mary University of London, the workshop convenes every two years at The Barts Cancer Instrtute, tts discuss a wde lange of topics relatin9 to the disease, attracting delegates from Ihe UK and abroad induding dinicians, saentists, phamiaceutical companies and chanties. The 2025 programme induded topics ol diagnostic studies, dinical trials, preclinical work to target pancreatic cancer and poster presenlalh)ns. We provided a range of our health information and support resources and had very engaging chats wth the event attendees. At the beginning of November, The UnNersty of Surrey research sludent that PCA supports hosted an event 'C8n We c8tGh it e8rliefi P8ncre8tlG G8nc&r awareness public perwectives- as part of the ESRC Festival of Social Science. We were proud lo attend the event with one of our volunteers who shared her experience as a pancreatic cancer survivor, providing an inspiring insight to why research is crucial to Improving survival. were grateful to have the opportunty to talk to attendees aboul the work of Pancreatic Cancer Action, and with the event aptly coinciding with Pancreatic Cancer Awareness Month share our Deadly Killer campaign and provide quick guides to pancreatic cancer. We will continue to champion innovative research. collaboration and meaningful patient invofvemenl. using our resources and influence to help turn promising ideas into opportuni1￿6 for earlier diagnosis. better treatrnenl and irnproved outcomes. S. Offer tho provljlon of prnctlcal and emO￿on￿l iupport and Inlonnatlon to all affected by pancreatlc ¢•n¢•r. People 8ffe¢ted by pan¢reali¢ cancer need information they can trusi. p8rti¢ularly when they are processing a diagnosis, considering Irealmenl or supporting someone dose lo them. Panc￿4￿¢ Cancel Action provides clear, practical Information covenng different stages of the panueatic cancer experience. Our resources are reviewed by appropriat&ty qualffied medical professionals and independently assessad through the pat￿nt Information Forum's PIF TICK accreditatsjn scheme. Patients, families, heatthcare professionals and other expert reviewers also contribute lo their developmenl. helping us ensure that the information is accurate, evidenc&based and accessible. Our modular booklets allow people to choose the infomiation most relevant to their needs. Resources a available digilalty through our websile. while printed copies can be ordered free of charge by individuals, hospitsls. cancer support cenlres and other organisations. Our specialist recipe book. Nouiishing Your Bcxly During P8nCle81￿ Cancer Trt8tmenl, ¢onlinues lo provide practical nutritional guid8ncè and recipès dèvèlop￿1 for peoplè affècted ty pancrèatic cancèr. Our guid8. rh8 Rol8 of G81J&tics in Pèncr88tAC Cancèr. explains inherited risk. 9enetic conditions associatèd with pancreatic cancer, genetic testing and the support availablè lo people who may be eligible for testing. It also highlights the signs and symptoms everyone should be awa￿ of. Developing and reviewing accfedrted heatth infom)ation is a thornugh and collaborative process. It invofves medical experts, peer and lay miewers, patients and families, heallhcare leaders and other charrties. This ensures that our resources remain accurate. relevanl and genuinety useful to the people who rety on them. Pancreatic Can￿r Action continued to fund a dedicated Pancreatic Can￿r Clinical Nurse Specialist within the Wesl of Scotland Cancer Nety￿r￿. Based at Glasgow Royal Infirmary. Ihe nurse works alongside the wider specialist tearn to provide information. guidance and reassurance to patients and farnilies across the legion. Support is provided in clinics. on hospital wards. al appointrnents and by telephone. The nurse also contributes to weekly multidisciplinary team Tneeting5. where heatthGqre ptofessionals review patient5, needs. di8gnose5 8nd treatment options and agree coordinated plans foi their care. Our funded nurse specialist worked with our team to develop a pilot project of Purple ca￿ Boxes and Chemo Care Bags, to provide practical support and reassuran￿ to people undergoing t￿atment for pancreatic cancer. These resources complemented our Irusted heatLh inf0m￿tIOn by helping people feel better prepared and supported during an exceplionalty difficult time.

PANCREATIC CANCER ACTION TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Our staff and volunte&rs also attend hospitsl awareness stands. creating opportunities to speak direcuy with patients and carers, listen to their concems and connect them wth relevant inft)rmation and support. Fundralslng In 2025. income was generated through a wide range of fvndraising aclivibes. and we are continually grateful to our amazing supporters and their inspiring energy. passmjn. detemiination and commrtment to raising funds and awareness lor p8ncreab'c cancer. Supporters participated in challenge events including The London Marathon, The Great North Run, The Great Scottish Run, The Edinburgh Marathon and various ￿￿alks, providing a shining example of the amazing events in aties across the UK. People braved skydives, bungee jumps and person81 challenges running. walking, swimming and clirnbing, with an inspiring delerminalion lo honour loved one$ 8nd help Pan¢reats¢ Can¢erAcb'on in our mission of Saving lives through early diagnosis. Schools. workplaces, hotels and communities took part in PJS for Pancan in April and during the Summer we encouraged people to host a"Bake. Brew and BBQ" event alongside marking our chantys 15hl year. Our long-term charity Partner Just Employment Law IJELI h05ted their bi-8nnual Summer B811 in June 2025, which was allended by over 500 people al The R8di$son Blu Hotel in Glasgow. raising tsver £105.000. We are $0 grateful for thè lantastic $upport from the JEL team and Iheir ne1w0￿. which ¢J&mon$tr8t&$ the power of corporate partnerships helping raise vrtal aWaren￿S and funds for pancreatic cancer. Community fvndraising activities look place throughout the year and we thank everyone who comes together to embrace the fun in fundraising and help change the pancreatic cancer slory. A 3peci81 thanks to our loyal fundraisers who hosl annual even15 from golf days and coffee momings. lo bingo nights and ¢olourful l¥a¢tor ¥un$ every year, ¢onlinualty embraong OPPOrtuniti&$ lo'Tum It Purple." Our virtual challenge "60 miles in Novemberf took pla￿ as part of Pancreatic Cancer Awareness Month, attracting people from across the UK to raise funds and awareness for pancreatjc Can￿r. Pancreatic Cancer Action's first ever rnatch-lvnding donation appeal took place in the first week of Decernbèr 2025. as p8rt ol The Big Give Chri5trnas Appeal. Wth thank5 lo pled9er$ and The Hospi181 Saturday Fund who provided match funding tts enable donations from geneious donois to be doubled, we $urpa$$ed our target and raised a total of £21,510 in 7 days. We thank our incredible donors who support Pancreaiic Cancer ActKJn throughoul the year and the kindness of people bequeathing legacy gifts to our charTty. Tru¥t¥ ond grants We are very grateful to the funders that generousty pmide grants to support our initiatives. actsvitses and projects. In 2025 these included gifts from The 8othwell Charrtable Trust and The Hospital Saturday Fund.

PANCREATIC CANCER ACTION TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Flnanelal re¥l•w The resutts for the year ar8 5ummaris8d in th8 Statement of Financial Aclivities on page 16. The Trustees 8re pleased to report that the charity's incoming iesouices for 2025 aTnounted to 1635.33412024.. £633,973), 12023." £752,504), 12022. £488,089), 12021". £754.2171, 12020." £1,256,477), an exceptional year which Induded a one-off transfer of £607,560 due to the merger ￿th Pancreab"c Cancer Scotland and £58,781 through the Coronavirus Job Retention Schemel12019'. £786.5051,12018.' £892.8511,12017'. £757,812). The Trustees would like to thank al those volunteers, fijndraisers and donors- ￿j￿Orate, trusts and foundations, as well as individual donors who have supported the charity over the past years and upon whom we are dependent. Total spending on ¢harrt8bl& 8¢tivrties was £422,563 12024." £492,318). 12023.. £465,441). 12022.. £450,195), 12021.. £513,8741,12020." £437,838112019". £609,931112018." £669,1871.12017.. £669,077). The charity achieve¢J a net deficit for the year of -£131,054 12024." -£222,4181, 12023." _£8,0771, 12022.. £- 241,7411.12021. £-87.7401,12020. £510.025112019. £-115,305112018. £-24,634112017. £-169,3151. R•s•Tho8 pollcy It is the policy of the charity that unrestricled funds which ha￿ not been designated for 8 5perific use should be maintained lo cover 81 le8s16 months ol operating expendl1u￿. The Trustees consider that reserves 81 thi$ level will Ènsure th81, in the èvenl ol a significant drop in funding, they will be abl& to continue the ¢harty'$ ¢urr¥nl 8¢tivitiès while consideration is gNen lo ways In whi¢h addiknonal funds may be raised. At 31st December 2025. the charity held reserves 01 £238.907 01 which £47.972 was restricted. Free reserves stood at £98,337, which is below our targel level. This reflected a combination of strategic investment in organisational assets to strengthen ouf long-tem) capacty and the impact ol a ChaI￿nging operaling environment lor charitie5 in the recent period. To ensure tsur cost base rern8ins aligned with projecte(J income, trustees planned a review of our operating model. including a restructuring lo reduce ongoing operaliny ¢o$l ¢ommitmenl$, which h8$ $in¢e btren completed. These changes have created a mre e￿ient and sustainable organisalion while protectin9 the qualrty of our services. We expect our reserves to strengthen over time as these effiaenues are realised and our income continues to diversify and grow. Rebuilding reserves remains a priority for the Board as part of our commrtment (o maintaining the organisation's long-lerm financial resilience. Structure. governance ond rnwno9ement The charity is a company limited by guaranlee. incorporated in June 2010, and is therefore govemed by rts Articles of Assoriation. Ils company registration number is 07272699 and lis charity numbers are 1137689 IEngland and Wales) and SC049777 (Scotlandl. Thè Trustees, who are also the directors lor thè purposè of company18w, and who seNèd during thè y8ar and up to the date of signature of the financial statements were.. N Menezès R Legg C Carter E Cowan N Longworth L Nylandei G Codaca Pisanelli D Slater G Lesca T Matthews IRe$i9ned 28 Odijber 20251 None of the Trustees has any beneficial interesl in the charity. The members of the o)mpany guarantee to contribute £10 in the event of liquidation.

PANCREATIC CANCER ACTION TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 The Trustees continu8 to keep the Chariws activities under r8view. patticularty wth iegaid to any major physical or financial risks that rnay arise from tsrne to time, and tts monrtor Ihe effectiveness of the systetll of internal controls and other variable means. including insurance cover where appropriate, by which those risks already identified by the Trustees can be mrtigated. Auditor In accordance with the companys articles, a resolution proposing that Mliotts LLP be reappointed as auditor of the company will be put at The Annual General Meeting and be subject to the requirements of audit. Dljrl￿Ur9 of Inforrnatlon to audltor Each ol the Trustees has confirnied that there is no inf0m￿tion ol which Ihey are aware which is relevant to the audit, but of which the auditor is unaware. They have fvrther Confinned thal they have taken appropriate steps to identify such relevant informatson and to eslablish thal the audrtor is aw8re of such information. The Trustees, report was approved by the Board of Tnjstees. ,J,. ca_, p,-.11, G Codacel Pl$an•lll Chair ol Trustees 18 Sep 2026 Dated.. 10-

PANCREATIC CANCER ACTION STATEMENT OF TRUSTEES, RESPONSIBILITIES FOR THE YEAR ENDED 31 DECEAIBER 2025 The Trustees, who are also the directors of Panueab"c Cancer Action for the purpose of company law, are responsible lor preparing the Trustees, Report and the financtal stalements in accordance with applicable law and United Kingdom Accounting Standards Iunited Kingdom GeneraltyAccepted Accounting Practice). Company law requires the Trustees to prepare ffinanryal $tslements for eadh fin8ncial year which gNe 8 true and fair view of the state ol aYfair5 01 the chanty and of the incoming resources and applicAtion of resouices, induding th8 income and expendrture, ol the charrtable company that yeaf. In preparing these financial statements, the Trustees are requifed to.. select suitable accounting policies and Ihen appty Ihem consislentty., observe the methods and principles in the Charrlies SORP.. Make judgernenls and esb'm8tes that are reasonable and pwdenl.. state whether applicable UK Accounting Standards have been followed, $ubie¢t to any material dèpartures disclosed and explained in the financial statements", and prepare the financial stalemenls on the going concem basis unless it 1$ inappropriate to presume that the ¢harfty 11 continue in operatson. The Trustees are responsible lor keeping adequale accounbng records th8t disdose wilh reasonable accuracy at any time the financial position of the charity and enable them to ensure that Ihe financial stalements comply wrth the Companies Act 2006. the Charilies and Trustee Inve$iment (Scotlandl Act 2005 and the Charities Accounts IS¢ollandl Regulations 2006. Thw are also re$pon$ibl& for $afeguardin9 th assts of th¥ ¢hgrrty and hence ftsr taking reasonable steps fof the Pfevenlion and delection of fraud and other irregularities.

PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION Oplnlon We havè audited financial ststements of Panueatic CanrAr Acbon Ithe 'charty'l for thè year ended 31 Decembei 2025 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the finanaal statements, induding signthcant accounb.ng poliaes. The financial reporting framework that has been applied in their p￿paratIOn is applicable law and Uniled Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland Iunited Kingdom Generalty Accepted Accountsng Pracb'rEI. In our opinion, the financial staternents.. give a tnje and lair view of the stale of the charitable companrfs affairs as at 31 December 2025 and of its incoming resources and application of resourcEs. induding its income and expenditure. for the year then ended.. have been properfy prepared in accordance wrth United Kingdom Generalty Accepted Accounting Practice,. and have been p￿pa￿l in accordan¢& vrith lh& reqU1￿MentS of tho Ccthpani&$ Ad 20rA, Ihe Charili&s and Trustee Investment (Scotlandl Act 2C*)5 and ￿gulatt"0n 8 of the chartti.es Accounts Iscotlandl Regulatlons 2006. Basls for oplnlon We conducted our audit in accordancè with Intèmational Slandards on Auditing ILIKI IISAS IUKII and appllcable law. Our responsibilities under those slan¢Jards are further described in Ihe Audilorfs ￿sponsIbl1111eS for the audit of the fin8nci&l stetemenls section of our report. We are independent of the charity in accordance wrth the ethical requirements that are relevant to our audit of the ffinancial statements in the UK, including the FRC'S Ethical Standard, and we have ￿￿illed OUT olher elhical responsibililbes in 8ccordance with these requirements. We believe that the audit &viden¢e we have oblained is suffi¢ieni and appropriate to pro¥id& a basis ltsr our opiniorn. Coneluslon8 r•latlng to golng eonc•m We draw attention to Note 1.2 to the finanual slatemenls. which sets out the Truslees, assessment of Ihe Charity's ability lo continue as a goin9 concern and Ihe basi3 on vthith the financial slalements have been prePa￿d. Th¥ Trust6eS' 8ssèssment acknowledges that the Charity is èxpèriencing cash llow pr&$$ures and is reliant on an improvement in financial performance and the generation of a¢Jditional income lo maintain suffiaent cash resources to meet its liabilrties as they fall due. The Trustees and management are aware of these pressures and have taken, and continue to take, appropriate action to manage the Charity's finanaal position. As Part of our audit. we have reviewed management'5 going concem assessment. induding the budgets. ¢88h Ilow forècasts and assumptions underlying the lorecasts. We have consKJerèd the actions being taken by managemènt to address the Chanty's cash flow position, induding the review of budgets and expenditure, cost-saving measures and the restructuring ol staffing arrangements. We have also considered the Charty's plans for future income generation, including antiupated legacies, grant applications and other fundraising activities. Based on Ihe work performed. we con5Kler management's assessment of going concem and the assumptions underlying the forec8sls lo be reasonable. We have 8150 considered the adequacy of the disd05ure5 made in Note 1.2 in respect ofthe Ch8nty's going concem assessment. Based on the audrt ewdence obtained, we have nol identffied any material uncertainty relating to events or conditions that, individualty or collectivety. may cast signthcant doubt on the Chanty's ability (o continue as a going concern. Accordingly. our opinion is not modified in respect of this matter. 12_

PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION Othar Infomiatoon The other information comprises the informalion included in the annual report other than the financial statements and our auditorfs report thereon. The Trustee5 are iesponsible for the othef Infofrnation contained within the annual report. Our opinion on the financial statements does not cover the other infomation and, except to the extent otherwise explicitly stated in our report, we do not express any forni of assurance conclusion thereon. Our responsibility is lo read the other inforniabon and. in doing so. consider whether the other infomiation is materially inconsistent with the financial ststements or our kn￿￿edge obtained in the course ol the audrt. or otherwise appears to be materially misstated. If we identfy suth material inconsislencie5 or apparent rnaterial mis5tatement5. we are required to determine whether this gives rise lo a fflaterial misstatement in the financial ststements themselves. If. based on the work we have perfomed, we conclude thal there is a matenal misstatement ol this other infomation, we are required to report that fact. We have nothing to report in this regard. Oplnlono on other matters prescrlbed by the Companles Act 2006 In our opinion, based on the work undertaken in the course ol our audit.. the information given in the Trustees. report for the finanri81 year for whKh the financial $18lemenls ar prepared, which includès thè diréctors, rèport pr&parèd for thè pufpos¢s of company law, 1$ ¢on$istènt wfth th& financial statements," and the directors, report included vrithin Ihe Trustees. report has been prepared in accordance with applicable legal requirements. Mattors on whlch w• aré r•qulr•d to f•port by •xeèptlon In the light of the kn￿edge and underslanding ol the ch8rity and ils environment obtained in the course of the audit, we have not identified material misstalements in Ihe directors, report included wrthin the Trustees, report. We hav8 nothing to rèport in respect of th8 following matters in rèlation to whKh the Compani¢$ Act 2006 and the Charities Accounts (Scotlandl Regulations 2006 require us to report to you rf. in our opinh)n. adequate and proper accounting record5 have not been kepl. or retums adequate for our audit have not been received Irom br8n¢hes not visited by us,. or the financial slalements are not in agreement wrth Ihe accounbng records and retums,. or c6rt8in disclosurès of trustèès, remuneration speufied by law arè not madè". or we have not receNed all Ihe information and explanations we require for our audit.. or the Trustees We￿ not entilJe¢J to prepare the finanoal stalemenls in accordance wth the small companies regime and take advantage ol the small companies. exemptions in preparing the Trustees, report and from the requirement to p￿pa￿ a strategic report. Responslbllltles of Trustees As explained more ful￿ in the statement of Trustees, responsibilrties. the Trustees. who are also the directors ol the charity for the purpose of company law. a￿ responsible for the prepara(H)n of Ihe financial statements and for being satisfied that they give a Irue and fair view. and for such intemal control as the Trustees deterrnine is necessary to enable the preparation of financial statements that are free from material rnisstaternent. whether due lo fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charty's ability to continue as a going concern, disdosing. as applicablÈ, rnattets related to going concem and using the going concern basis of accounting unless the Trustees erther intend to liquHYate the charitable company or to cease operations, or have no realistsc altematNe Lwjt to do so. 13-

PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION Audltorfs r&sponslbllbtl•s forth• audlt of the financlal ststemènts We have be8n appointed as auditor under section 4411 Ilcl of the Cha[1t￿S and Trustee Investment Iscouandl Act 2005 and under the Cofflpanies Act 20(￿ and report in a¢xordance wrth the Acts and ielevant regulations made 01 having effect thereunder. Our objectives are to obtain reasonable assurance aboul whether the finanaal slatements as a whole are free from material misslaternenl. whether due lo fraud or error. and lo issue an audilorfs report that includes our opinion. Reasonable assurance is a high level ol assurance but is not a guarantee that an audit conducted in accordance with ISAS IUKI will 8fv4ays detect a material misstatement when it exists. Misstatements can 8rise trorn fi8ud or error and are ¢onsidered material il, individualty or in the a99reg*e. they could ieasonabty be expected to influonc the economlc decisions of users taken on the basis of Ihese finanual statements. Irregularities. including fraud, are instances of non-compliance wilh laws and regulations. We design procedures in line with our responsibilrties, oullined above. to detect material misstatements in respect of irregularities. induding fraud. The extent to which our procedure5 a￿ capable of detecting irregularities. including fraud, is detsiled below. Extent to whlch the 4udlt wo¥ con?IdeTrd c?pablg of detectlng Irregul¥rlt1￿, Includlng fraud Our approach to identifying and assessing the nsks ol matenal misstatement In respect of irregularilles. Induding fraud and non-compliance with laws and regulations. was as follows". the engagement partner ensured Ihal the engagement team collectivety had the appropriate competence, capabilities and skills to identify or recognise nonllc0mp1ian￿ with applicable laws and regulations.. we identified the laws and regulalions applicable to the company through discussions wrth Trustees and other rn8n89emenl. and from our knowledge and experience ol the sector.. we focused on $petyfi¢ 18ws and regulations which we ¢onsidered may havo a direct material efttr¢t on Ihtr financial statements or the operations ol the chantable company. including the Companies Act 2006, the Charrties Act 2011, the Charities SORP. taxal￿n legislabon. data protection, anti-bnbery, employment, environrnenlal and heahh and safety legislation.. we assessed the extenl of compliance with Ihe laws and regulabons idents'fied above through making enquiries of rnanagernenl and inspecting leg81 correspondence.. and identrfied laws and regulations were ¢ommuni¢aied within the audrt leam regularty and the team remained alert to instances ol non-compliance throughout the audrt. We assessed the suscepltbSltty ol the charitable company's finanaal statements to material misstatèment. Including obtaining an understanding of how fraud might occur. by.. making enquiries of rnanagemenl as to where they conSide￿d the￿ was susceptibility to fraud, their knowledge of actual. suspected and alleged fraud.. and considering the internal controls in place lo mitigale risks of fraud and non-compliance with laws and regulations. Audlt rnspon8• to rfsks Id•ntlfi•d To a¢Jdress the nsk offraud through management bias and override of controls, we." performed analytical procedures lo identfy any unusual or unexpected relationships,. reviewed all transactions listed.. a55es5ed whether judgemen15 and assumptions made in determining Ihe accounting e5timale5 were indicative of F)Otenlial bias", and investigated the r8ts"onalè behind signifi¢Ant or unusual transactK)ns. In response to the risk of irregulanlies and non-complian￿ vthh laws and regulab"ons. we designed procedures which included, bul were not limited to.. agreeing financial staternent disdosures to undertying sUppO￿.ng dowmentstion.. and enquiring of management as to actu81 and potenbal liligalion and daims. 14_

PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION There are inherent Iimrtabons in our audit prO￿dureS described above. The more removed that laws and regulations are from finanaal transactions. the less like￿ il is Ihal we would become aware of non-compliance. Auditing standards also limit the audit prC￿dU1eS required to identify non-compliance with laws and regulations to enquiry of the Trustees and other management and the inspeclion of regulatory and legal correspondence, rf 8ny. M8t81i&l mi5Statements that arise due to fraud (*n bè hArdèr to dètèct than thtssè that aiise from orror as thèy MAY involve deliberate concealment or collusion. A further description of our responsibilities is available on the Finanaal Reporting Council's website at.. https'.11 w¥vw.frc.org.uklauditorsresponsibilities. This description forms part of our auditorfs report. U89 of our rgport This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 01 Part 16 of the Companies Act 2006. and lo the charilable company's trustees, as a body. in accordance with Regulation 10 of the Charities Accounts Iscouandl Regulabons 21￿. Our audrt work has been undertaken 50 that we might state lo the charrtable cornpany s members and iruslee5 those matter5 we are required to state to them in an auditor's report and for no other purpose. To thè lullesl extent pemirtled by law, we do not a¢¢ept or assume responsibility to anyone other than thè charrtable company, thè chanlable company's members as a body and the charitablè company's trustees as a body, for our audit work. for this report, or for the opinions we have lomied. St•phen Meredlth BA FCA DChA IS•nlor Statutory Audltorl for ond orb behall of Alllotts LLP 21 Sep 2028 Chart•r•d Accountants ststulory Audltor 3 London Squartr Cross Lanes Guildlord GU1 1UJ 15-

PANCREATIC CANCER ACTION STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2025 Unrestrlcted Restrlcted lunds funds 2025 2025 Total Unrestrlcted Restrlcted funds funds 2024 2024 Total 202S 2024 Notes Incom• frt>m= Donations and legacies Other trading activities Investments 19.607 629.267 2.354 3.713 594.096 2.943 7.670 29.264 623.360 2,943 7.670 2,354 3.713 Totsl Incorn? 615,727 19,607 635,334 604.709 29.264 633,973 Expendlture on.. Raising funds Charltablè activlti8$ 339.749 351,564 4.078 70.999 343.825 422.563 322.757 317.928 41.316 174,390 364,073 492,318 Totsl •xp•ndltuM 891,313 75.07S 786.388 640.68S 21S.706 856,391 N•t •xp•ndltuM 175,586) ISS,4681 1131.0541 13S.9781 1186.4421 1222,4181 Transfers behyeen funds {6.0931 6.093 N•1 mov•meni In funds 175,586} 155,488) 1131.0541 142,0891 1180,3491 1222,4181 R•conelllatlon of lundg: Fund ba18nces 811 January 2025 266,521 103,440 369.961 30B,S90 283,789 S92,379 Fund balanc•8 at 31 December 2025 190,935 47,972 238.9)7 2e6.S21 103.440 369,961 The statement of financial aclivth&s indudes all 9ains and kjsses reco9nised in the year. All income and expendrtur6 derive from continuing activities. 16-

PANCREATIC CANCER ACTION BALANCE SHEET AS AT 31 DECEMBER 2025 2025 2024 Notes Flxed assets Intangible assets Tangible assets 12 13 74.503 18.095 46,012 27.253 92.598 73,265 Current a8set8 Stocks Debtors Cash al bank and in hana 14 15 9.378 84.869 109.110 4.565 54.375 331.620 203.357 390.560 Credltors.. arnounts folllng due vAthln on• yoor 16 157,0481 193,8641 Nèt eurmnt a88èts 146,309 296,696 Totsl a8S•t8 1•88 eurr•nt Ilabllltl•8 238,907 369,961 Th• fund$ of th• ¢horlty Restricted incorne funds Unrestricted lund$ 18 47.972 190,935 103,440 266,521 238,907 369,961 18 Sep 2026 The flnanclal statem8ntS W8r• approvèd by the Trust8e$ on ......................... &,J,- ￿.-. p. 11, IIIB G Codaccj Pisanelli Chalr ol Tru•tO•8 17_

PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEAIBER 2025 2025 2024 Note$ Cash flows from opèrating aetlvltl•s Cash absorbed by operatsons 22 (191.223} 1142.0261 Inv•stlng actlvltl•s Purchase of intangible assets Purchase of tangible fixed assets Investrnent income received 135.000) 147.1401 132,6001 7.670 3.713 Net cash used In In¥￿tIng acWvllle• 131.287) 172,0701 N•t ¢o¥h gon¢ratod from flnan¢lng •¢llvlW¢s Nèt d•er•asè In eash and eash •quIva￿nts 1222.5101 1214,0981 Cash and cash equivalents at beginning of year 331.620 S45,716 Cash and ca8h equlvalents at •nd of year 109.110 331,620 18-

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEAIBER 2025 Aecountlng pollel•s Charfty Snforniatlon Pancreatic Cancer Action is a registered tharrty and a company Incorporated by guarantee with no share capital, exempted under section 5 of the Companies Act 2006 from the requirement to use 'Limrted" as part of its name. It is incorporated in England and Wales undef registration number 07272699 and its registered office is 3 London Square. Cross Lanes. Guildlord. England. GU1 1UJ. Correspondence address is Suite 3.10 Covautt. Fullarton Road. Cambuslang. Glasgow. G32 8YL. 1.1 Ba$1# of preparatlon The financial statements have been prePa￿d in accordance wlh the charitys Statement ol Recommended Practi￿ applicable to charities preparing accounts with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021. the Companies Act 2006. the Charities and Trustee Investment IScoll8ndl Act 2005, tre Ch8rilie$ Acwunts IScoU8ndl Regulations 2006 18$ arnendedl, FRS 102 'The Finanryal Reporting Standard applicable in the UK and Republic of Ireland. I"FRS 102.1 and the Charrties SORP "Accounting and Reporting by Charities." Statement ol Recommended Practice applicable to charities preparing their accounts in accordance wth the Financial Repo￿n9 Standard applicable in the UK and Republic ol Ireland IFRS 1021" (effective 1 January 20191. The charity is a Public Benefit Entity as defined by FRS 102. Th& finan¢i81 siatemenis 8r& prepared in Slerting, which is the ftJn¢b'onal curnency of th¥ ¢harity. Mon&tsry amounts in thèse financial statement$ ar& rounded lo th¢ n&ar¢$l £. The financial statements have been prepared under the historical cost CA)nvenbon. The principal accounting policies adopted are set out below. 1.2 Golng concern The Trustees have assessed Ihè Charrty's ability lo continue as a 9olng ¢on¢em for a pèrfod ol at least twelvè months from the date of approval of these financial slalements. In making this assessment, the Trustees considered the Charity's current ffinanaal position, cash flow lorecasls and the prinupal risks and Un￿rtaIntieS lacing Ihe organisation. The Trustees recognise that the external environment lor charitse8 remains chaMen9ing. wrth wnbnuing pre6sure6 on income generation. funding and operating costs. During the year, the Chanty has un(Jertaken a programme of significant COSt-saving measures. including a restructuring of siaff, to Ènsure th81 expenditure 15 81ignÈd wilh antitypated levels of in¢ome and to Stienglhen the Charty's long-term financial sustainabilrty. Cash flow lorecasts are preparèd lor règular ièvièw by thè Trustees to ensure reasonable cOns￿eration of possible downside scenarios. Having ￿VIeWed the Charity's financial forecasts, cash flow projections and available reserves, together wrth the actions available to managemenl lo respond to changes in income or expenditure, the Trustees are satisfied that the Charity has adequate resources lo continue rts operations for a period of at least ￿e1ve months from the dale of approval of these financial slalemenls. The Trustees the￿fOre have a reasonable eKpectation that the Charity ￿11 conty'nue as 8 going fg)nr*m and have adopted the going ¢on¢em basis in preparing these financial Statements. 1.3 Charitable funds Unrestricted funds are available for use al the discreb.on of the Trustees in furtherance of their chantable objectsves. Restricted lunds are subject to specthc cOndrt￿ns by donors or gtantors as to how they may be used. The purposes and uses ofthe restricled lunds are set out in the notes to the finanaal statements. 1.4 Incom• Income is recognised when the charity is legalty enlitled to it after any perfomiance conditions have been rnet. the arnount5 can be rneasured reliabty. and rt 15 probable th8t inwme will be received. 19-

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Accounting policies (Continuedl Cash donations are recogniseil on receipt. Other donath.ons are re(x>gnised once the charty has been notified of the donation, unless perfomiance condib.ons require deferral ol the amount. Income tax recoverable in relation to donations rece￿ed under or deeds ol covenant is recognised at the time of the donation. Legacies are recognised on receipt or olhemse il the charity has been notified of an impendin9 distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy Is treated as a contingent asset. Glfts ol assets and sgrvi¢es a￿ r¥¢ognised at market Value to ¢harity. 1.5 Exp•ndltur Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third paty. il is probable that a Iransfer of e￿nOMiC benefits will be require(l in settlement, and the arnounl of the obligation can bo measured reliabty. Expenditure is dassified by actwity. The costs of each activity are made up of the total of direct costs and shared costs. including support costs involved in undertaking each acbvity. Direct costs attributable to a single activity are allocated directy to that activity. Shared costs which conlribule to more than one activity and support costs which are not attributsble to a single aclivity are apportioned befv4een those activities on a basis consistent wrth the use of resources. Cenlral staff costs are allocated on the basis ol lime spent. and deprwotlon ¢h8rge$ ¥r¢ •llo¢ai¢d on th ports.on tsl lh¢ ass¢i'$ ustr. Expenditu￿ has been allocated betsyeen the main headings in the Statement of Financial ActNth'es on the basis of the type ol activity to which they relate. induding irrecoverable V.AT. Income and expenses have not been netted off. 1.6 Intanglbl• Ilx•d assèts oth•r than goodwlll Intangible assets acquired 5eparalety Irom a business are recognise(181 cost and are subsequently measured 81 cost le$$ accumulated amtsrtisalion and ac¢umul*èd impaimènt lo$￿$. Intangible assets acquired on inlemalty generated assets are recognised at the acquisition date where it is probable that the expected fu1U￿ economic beneffts Ihal are attributable lo the asset will flow to the entity and the fair value ol the asset can be measured reliabty.. the intangible asset arises trom contractual or other legal righls.. and the intangible asset is separable from the entity. Amorh'sation is recognised so as lo write off the cost or valualion of assets less their residual values over their useful INes on the follrring bases.. Sofvlare Websf¢e De¥elopmenl Cost 33.3% on cost 14.3% on ry)s1 1.7 Tangible fixed assets Tangible fixed assets are initialty measured at cost and subsequenty measured at cost or valuation, net of depreciation and any impairmenl losses. Depreuab"on is recognised so as to vnite off the cost or valuation of assets less their residual values over their useful lives on the following bases". Flxtures, ffith.ngs & equipment Computers Motor vehides 25%-33.3% on cost 25% on cost 25% on cost -20-

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Accounting policies (Continuedl The gain or loss arising on the disposal of an asset is detemiined as the dtherence between the sale proceeds and the carrying value of the asset. and is recognised in the statement of finanual ath"wties. 1.8 Impainngnt of fixgd as¥et¥ At each reporting end date. the charity reviews the carying amounts ol its tangible and intangible assets to determine whether there is any indicalion that those assets have suffered an impairrnent loss. If any such indication exists. the recoverable amount of the assel is estirnated in order to determine the exient of the imp8irtnent loss lif any). 1.9 Stocks Stocks are stated at the lower ol cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable. direct labour costs and those overheads that have been incurred in bringing the stocks lo Iheir presenl Ic￿￿On and condition. Items held for dislribulion at no or nominal consideration are measured the lower ol replacemenl cos¢ and cost. Th¥ ¢harity 1$ r8cogni$in9 80% ol the $t¢xk a$ $lo¢k i$su&$ lo support a¢livilles ralsln9 fund$ and awaren&$$. The balance recognisetl on Ihè balan￿ shèet 1$ the r¢$idual value of the stock. Nel realisable value is the trstim8led selling pri¢& less 811 esiimaled ¢o$ls of completion and co81$ lo be in¢urre¢J in markeling, Selling ana dislribulion. 1.10 Cash and ea8h oqulval•nts Cash and cash equivalents include ¢a$h in h8nd. deposrts hekl at ¢811 with banks. othtrr $hort-lerm liguid inveslrnenls with original maturities ol Ihre& monlhs or less, and bank overdr8ft$. Bank overdrafts are Shown wbthin borrowings in curnent 11a￿lrt￿S. 1.11 Flnanclal In8trum•nts The charity has elected lo appty the provision$ of Sedion 11 '88$i¢ Fin8nu81 In$trumtrnls' and Section 12 'Other Flnandal Instwments Issues, of FRS 102 to all of rts finanaal instruments. Flnancial instrurnents are recognised in the chanty's balance sheet when the chanty becomes party to the contradual provisions of the instrument. Financial assets 8nd liabilitie5 are offset. wilh Ihe net amounts presenled in the financial statements, when there 1$ 8 legalty enforceable right lo Sel off the re¢ognised amunts and there is an intention lo settle on 8 net basis or to realisè th6 assèt 8nd sètuè thè liability simuM8neousty. Baslc flnanclal ass•ts Basic financial assets. which indude debtors and Gash and bank balances, 8re initially me8sured at transaction price including transaction costs and are subsequenuy ¢Arried at amortised cost using the effective interest method unless the arrangement constrtules a finanang transaction. where the transaction is measured at the present value of Ihe luture receipts discounled at a market rate of interest. Finanaal assets classified as r￿1Vable wrthin one year are not amortised. 21

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Accounting policies (Continuedl Basle finanelal Ilabilltiès Basic finanrial liabilities. induding credrtors and bank loans are inrtially recognised at transaction price unless the arrangement constrtutes a financing transaction. where the debt instwment is measured at the present V81ue of the future payment5 discounted at a market rate of inlere51. Fin8nryal li8bilities classified 85 Payable wrthin one year are not amortised. Debt instruments are subsequentty carried at amortised cosl. using the effective interest rate method. Trade creditors are obligations to pay lor goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable 8re dassified as current liabilities if payment is due wlhin one year or le$5. If not. they are presented a5 non-current liabilities. Trade creditor5 are recogni$ed inth'ally 81 transactKJn price and subsequentty measure(1 at amortised cost usin9 the effectsve interest method. D•rncognitlon of financlal liabiliti•s Financial liabilities are derecogni5ed whtrn thtr Charty's ¢ontr8dual oblig81ion$ expire or a￿ discharged or ¢8ncelled. 1.12 Employe• b•n•fit8 The cost of any unused holiday trnlrflemenl is recooni8ed in thtr period in vthi¢h the employee's se￿￿8 arts received. Termination beneffts are recognlsed immediately as an expense when the charity Is demonstrably cornm￿ted to temiinate the employment of an employee or to provide terniinalion beneffts. 1.13 Retlrem•nt benefits Payments to defined contribulK)n retirement benefft schemes ara charged as an expense as they fall due. crttlcal accoUn￿n9 estlmates and judgements In the application of the ¢harity'5 accovnting poliryes. Ihe Trustees are required lo make judgement5. estimate5 and assumptions aboul the carrying amounl ol a$5eis and liabilrties that are not readity apparent from other sour¢es. Thè Èstimates and associaièd assump￿.0￿$ are basèd on hi$torieal experion¢g and other factors that are considered to bè relevant. Actual resums may differ from these estimates. The estimates and undertying assumptions a￿ reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the eslimale is revised where Ihe revision affects only that period. or in the period ol the revision and ftjture peiiod5 where the revision affects bolh current and future peri¢xls. Kèy 8oure•# of •8tlmatlon uneèrtaonty Falr value of Glfts In Klnd The trustees have exercised judge￿nI in recoynising 8nd valuing grfts in kind. including donated goods 8nd services. Recognition is made when entrtlement ts established, receipt is probable, and value can be ￿I1abty measured. Fair value is based on estimaled markel pri￿$ or equr¥alenl services rates at the dale of donation. -22_

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Ineom• from donatlons and legael•s Unrestrlcted Restrlcted funds lunds 2025 2025 Total Unrestrlcted Restrlcted funds funds 2024 2024 Total 202S 2024 Donations and gffts Legacies Grants receivable for core 8Ctivrties 17,607 626.267 1.000 581.248 12.848 11.264 592.512 12,848 1,0 1B.000 18.000 19,607 629,267 594.096 29.264 623,360 Income from other tradlng acVvltle¥ Unrnstrl¢t•d Unmtrl¢tgd funds funds 2025 2024 S81&s ol merchandise 2,354 2,943 Income trom Investment¥ Unmirf¢t•d Unrostrl¢t¢d funds funds 2025 2024 Interest re¢eivable 3,713 7,670 -23-

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Exp•ndltur• on ralslng funds Unrestrlcted Restricted funds funds 2025 202S Total Unrestrlcted Restrlcted funds funds 2024 2024 Total 202S 2024 Fundraising and publicity Fundraising costs Stsff co$1$ Depreciation and imp8irment Support and govemance costs 125,054 175,410 125,054 175.410 117.927 159.204 117,927 196,905 37,701 5.147 5.147 28,434 4,076 32,510 29.805 3,615 33,420 334.045 4.076 338.121 307.600 41.316 348.916 Tradlng costs Other tradin9 activitie$ 5,704 5.704 1S.157 15,157 Total costs 339,749 4.076 343.825 322.757 41.316 364,073 Exp•ndltur• on charftsbl• actlvltl•• Ralslng Supportlng Medlcal Patlent awarene ruearch educatlon 8UPPOrtllnfo natlon 2025 Total 202S 2025 202S 2025 Dlrect costs Staff costs Depreciation and impainnent Other costs 144,601 8.855 104,553 18.461 500 13.348 20.314 518 14.686 33,017 647 23,873 216,393 10.520 156,460 258.009 32,309 35.518 57,537 383,373 Share of support and governance cosls Isee note 9) Support 19,651 Governance 6.537 2,509 835 2.760 918 4,487 1.493 29,407 9.783 284.197 35.653 39.196 63.517 422.563 Analysis by fund Unrestricted funds Restricted funds 261.767 22,430 21.892 13,761 26.530 12,666 41.375 22,142 351.564 70,999 284,197 35,653 39.196 63.517 422,563 -24_

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Expenditure on charitable activities (Continuedl Prèvlous yèar= Ralslng Supportlng M•dleal Patl•nt aVArèn•ss rèsearch èducatlon supportllnfo miatlon 2024 Total 2024 2024 2024 2024 Dlrèct costs Stsff costs Dep￿CiatIon and impaimient Other costs 167.421 5.592 124.494 18.133 45 12.386 36.700 93 29.387 32.435 81 22,154 254.689 5,811 188,421 297,507 66,180 54,670 448,921 Shar• of support and gov•mane• eosts188• notè 91 Support 21.264 Governance 7,282 2.303 787 4.661 1.592 4.121 1,407 32.349 11,048 326,033 33,654 72.433 80,198 492,318 Analy81s by fvnd Unrestricted funds Restricted ftjnds 229,859 96,174 13.818 19,836 44.678 27.555 29,373 30,825 317,928 174,390 326,033 33,654 72,433 60,198 492,318 Tru•te Non& ol the Twslees lor any persons ￿nn¢¢I&<I vnlh Ih¥ml r￿1¥&4 any ￿muneration durin9 the year and none of them wgre fgimburs$d trav¢lling *x￿n$￿$(2o24- ÉNill. -25-

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 Support eosts alloeat•d to aetlvltl•s Support Governance eosts costs Support Governance costs costs 2025 2024 Rent Office costs Telephone costs Computer costs Insurance Staff welfare Training. recruitment and internship costs Book-keeping and accountancy Bank charges Audit fees L89al and professional 14,941 1.052 1,480 17.679 2,768 1,809 14.941 1.052 1.480 17.679 2.768 1.809 18,970 3.724 2,857 18.692 3,327 1.909 18,970 3.724 2,857 18.692 3,327 1,909 10.550 10.550 4.501 4.501 3,354 170 3.354 170 14.928 3,082 199 3,082 199 14,500 14.928 14.500 2,￿9 2.969 5,056 5,058 53,803 17.897 71.700 57.261 19.556 78,817 Analysed befv4een Fundraising Charitable activities 24.3 29,407 8.114 9,783 32.510 39.190 24.912 32,349 8.508 11,048 33.420 43,397 53,803 17,897 71.700 57.261 19.558 78,817 Governance costs include paymenls of £9,20012024 - £8,7501 plus VAT for audit fees and £3,04512024'. £2,900) plus VAT for account5 preparalion fees. 10 Employèès The average monthty number of employees during the yearwas= 2025 Number 2024 Number 13 -26-

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 10 Employees (Continuedl Employmènt Costs 2025 2024 W8ges 8nd $818ries Soaal security costs Olhei pension costs 345.797 36,440 9,566 406,678 34,851 10,065 391,803 451,594 There were no &mploy&es whose annual remuneralK)n was MO￿ than £60.IXIO. Ramunèratlon ol kay manag•m•nt pèrnonn•l The remunerakn'on ol key management pef8onnel is as follows. 2025 2024 Aggregate ¢ompen$allon 61,684 52,429 The key management per$onn¥l of the Chanty 1$ ¢on$idefd lo be ¢h& CEO. Th& In¢ras In KMP remuneration 1$ due lo 8 ¢ross-ov&r of CEO'S durin9 the yè8(. 11 Taxatlon The company is a registered charity and is. therefore. exempt from taxation on its charitable acts'vities. 12 Intanglble flxed a¥sets Solts•r• Wèbilt• D•v•k+pment Coit• Total ¢￿t Al 1 J8nu8ry 2025 Additions- internalty developed 12.140 35.000 35.000 47,140 35,000 At 31 December 2025 12.140 70.000 82.140 Amort18ation and irnpairment At 1 January 2025 Amortisation tharged for the yèar 1.128 4,006 1.128 6,509 2,503 At 31 December 2025 5,134 2,503 7,637 Carrylng amount At 31 December 2025 67,497 74,503 At 31 December 2024 11,012 35,000 46,012 -27_

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 13 Tanglblè (lx￿ ass•ts Flxtures. fftUng$ & Computers Motor vehl¢les Totsl C￿t At 1 January 2025 18,032 6,758 20.000 42,790 At 31 December 2025 16.032 6.758 20.000 42.790 Dgpreclatlon and Impolnnont At 1 January 2025 Dèpreciation charged in the y&ar 3,779 4,158 6,758 5.000 5,000 15,537 9,158 At 31 Do¢ember 2025 7,937 6,758 10,000 24,695 Carrylng amount Al 31 December 2025 8,095 10,000 18,095 Al 31 December 2024 12,253 15,000 27,253 14 Sto¢k8 2025 2024 Flnl$hed goods and good$ lor rèsalg 9.378 4,565 10 D•btor• 2025 2024 Amounts lalllng du• wlthln on• yèar: Prepayments and accrued income 84,869 54,37S 16 Cr•dltor8'. amounts falllng du• wothon on• yèar 202S 2024 Other taxation and social seujrity Trade creditors Other credrtors Accruals and deferred income 11,011 8,954 156 36,927 12,171 36,322 19.265 26,106 57,048 93,864 -28-

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 17 R•tlr•m•nt ￿n&fit seh•m•s 2025 2024 Defined contrlbutlon scheme8 Charge to the Staternent of Finanaal ACtiv￿e$ in respect of defined contribution schemes 9.586 10.065 The charity operates a defined cx)ntribution pension scheme for all qualifying employees. The assets of the scheme 8re held separatety from those ofthe charity in an independenuy 8dministered fund. 18 R•strfet•d lund$ The restricted funds ol the charity comprise the unexpended balances of donations and grants held on trust subject to specAfic conditions by donors as to how they may be used. At 1 January 2025 Incomlng Source¥ Resourceo ?xpended Trnn8fero At31 Dec?mber 2025 Pat & Paul Powapp Recipe Book PC Aware Campaign Patiènt Infomalion Booklets NIPanC Research Pancreatic Cancer Scotland 22,007 17.200 6,432 17.607 139.6141 17,200 4,427 500 {2.0051 {7.0001 5.845 22,000 24.456 5.845 20,000 12,0001 124.4561 103.440 19.607 175.0751 47,972 -29-

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 18 Restricted funds (Continuedl Prèvlous yèar= At 1 January 2024 Ineomlng rnsoure•s R•soure•s •x￿nd•d Transfèrs At31 Deeember 2024 Pat & Paul Powapp Recipe Book PC Aware Campaign HCP Education Patient Information Booklets NIPanC Translation of resource Research Pancreatic Cancer Scotland PC Aware North East England A¢tion on th¢ Ground Glasgow Project Community volunteers 21.189 17,200 10,645 11.264 110.446 22.007 17,200 6,432 500 {4.213) 15.0001 {4.3201 {6.2731 5.500 3,500 8.000 820 5.273 5.000 5,845 5,845 493 22,500 175.197 20,000 1493 13,5001 1150.7411 120.0001 22,000 24,456 9,780 {9,7601 19601 283,789 29.264 1215.7C61 6,093 103,440 Reslricled ftjnds relaie 10 9rant$ received for Ihe $petyfi¢ purposes a8 Set out above. Any 8mounl unspent 18 carried lorwar¢J lo b¥ spent in ¢he next finon¢i81 year. 19 Analy•l8 of nèt a88•t8 b•twn fund• Unmtrf¢ted funds 2025 Rstrl¢t¢d funds 2025 Totgl 2025 At 31 Dec•mb•r 2025: Intangible fixed asse15 Tangible assets urrenl 8ssets1lliabilttiesl 74.503 18,09S 98.337 74,503 18,095 146,309 47.972 190,935 47,972 238,907

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 19 Analysis of net assets between funds (Continuedl Unr•strlet•d fund8 2024 Rèstrfctèd funds 2024 Total 2024 At 31 December 2024: Intangible fixed assets Tangible assets Curr8nt assetsllliabilrti¢sl 46.012 27.253 193.256 46,012 27.253 296,696 103,440 286.521 103,440 369,961 20 Flnanclal commltm•nts, guarants•8 and contlngent Ilabllltl To d8te, the charity h85 received £49.165 12024.. £48,235) in donalions from 80lirytors relating to old monies held in dienl 8ccounl$ 1£18.979 < 5 years and £30.187 > S years) which they have ng1 been able lo rtrlurn. There is a possibility that in the lutufe the dienls in question could still retum for these monies and, as such, the charrty has agreed to refund part of the ¢Jonabon il Ihis occurs. No provision has been made In these finanual statements for any possible refund as Ihe likelihood is remote and cannot be quantified, particularly given the age of the undertying balances. The Charity has committed lo sponsor a nursing ptsst vrithin NHS Greater Glasgow & Ctydtt IGGCI for a further thre& year period, following the original thre& year commitment which $lart&d in January 2023. Th& lot81 r$m8ining commilm¥nt a$ at O¥¢embef 2025 is É137,11212024". È46.8741. During the year, the charity also r￿mmItted to paying for chanty insurance and for PR & Media Outreach and monitoring seNices. The remaining wmmitmenis oulslanding al the year end are £782 and £2.325 respectively. 21 Related party tron¥•cllon• There were no disdosable related party transactions during the year12024- none). 22 Cash absorbed by operntlons 2025 2024 Deficit for the year 1131,0541 1222,4181 Adlustrnents for.. Investment income recognised in statement of finanual activitse$ Depreciation and impaimient of langible fixed assets 13,7131 15.667 17,6701 8.475 Movement5 in working capital= Ilncreasel in stocks Ilncreaselldecrease in debtors IDecreasellincrease in Creditors 14.8131 130,4941 136.8161 18901 24,823 57.654 Cash absorbed by operations {191.2231 1142.0261 31

PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEAIBER 2025 23 Analysls ol Changès In nèt fvnds The charity had no material debt durin9 the yeai. -32_